Having been subject to a harsh reality check over the last year or so, the ASX listed cannabis sector is applauding the local medicine regulator’s endorsement of the weed as an effective therapy that should be more freely available to the ailing masses. But the path to the pharmacy is likely to be harder than
Read More
Despite a gloomy day on the ASX yesterday, Australian cannabis companies ended it very well upon news of the Therapeutic Goods Association (TGA) announcing they will amend legislation that will open a clear path for Australians to purchase cannabidiol (CBD) products without a prescription. The notice of interim decision was released confirming that the TGA
Read More
Global pharmaceutics and cannabis healthcare company Althea Group (ASX: AGH) has harnessed the power of telehealth through COVID-19, almost doubling web-based enquiries for their MyAccess Clinics in the UK where patients can seek medicinal cannabis treatment pathways. With the England being one of the harder nations hit by COVID-19, Althea accelerated telehealth offerings for its
Read More
Australian-based Medical Cannabis producer and supplier, Althea Group (ASX: AGH), have announced this morning that their Bristol-based medical clinic site has secured a licence from a UK independent health and social care regulator. The news suggests that medical cannabis is becoming increasingly accepted in the UK as a treatment option for chronic health conditions. Wholly
Read More
Medicinal cannabis company Althea Group Holdings (ASX:AGH) has announced record prescription numbers for their medicinal cannabis products in the month of July which has been consolidated by two major corporate partnerships. Prescriptions of the Group’s medical cannabis products increased by 334 patients in the month, bringing the total to 1,523 for the company which listed
Read More